Acute Oral Toxicity Study on
|
|
- Thomasine Tucker
- 6 years ago
- Views:
Transcription
1 Acute Oral Toxicity Study on MAKARDHWAJ RASAYAN TABLET OF Sponsor Study Centre: VIRGO UAP PHARMA PVT.LTD. PHARMACOLOGY LABORATORY MAHAGUJARAT IND.ESTATE, SDM CENRE FOR RESEARCH IN PLOT NO. 423/98-B. AYURVEDA AND ALLIED SCIENCES SARKHEJ BAVLA HIGHWAY LAXMI NARAYANA NAGAR, KUTHPADY, VILL MORAIYA, TA SANAND UDUPI DIST AHMEDABAD contact@virgouap.com Web:
2 STUDY REPORT Evaluation of Makardhwaj Rasayan Tablet for safety profile Acute Oral Toxicity Study Project Director Dr. B. Ravishankar Chief Investigator Mr. Ravi M Pharmacology Laboratory SDM Centre for Research in Ayurveda and Allied Sciences, Kuthpady, Udupi
3 INDEX Title Page No. Index 3 Investigators conclusion 4 Details of experiments 5 Materials and methods 6-9 Observation and Results 9-10 Conclusion 12 Data sheets (Proforma records)
4 Acute toxicity study: This study determines acute toxicity of Makardhwaj Rasayan Tablet an oral formulation prepared with suspension of test drug using gum acacia, in rats was assessed for single dose acute toxicity by employing OECD guidelines 425 using AOT software. The dosed (up down as per requirement) rats were observed for 14 days, for general appearance, cage side behaviour including increased or decreasing motor activity, convulsions, straub s reaction, catatonia, muscle spasm, spasticity, ophisthotonus, hyperesthesia, muscle relaxation, anaesthesia, arching and rolling, lacrimation, salivation, diarrheal, writhing movement, mode of respiration and changes in skin colour etc., with mortality and autopsy finding in case of dead animal. Conclusion: The test drug did not produce any mortality up to the dose of 2000mg/kg per oral which is equivalent to 22.4g total dose for a human being weighing 70 kg man. At the dose level studied the drug also did not produce any observable toxic effect except for mild irritation in animal in the dose550mg/kg and 2000mg/kg. Based on the observation made and recorded it can be concluded that the test drug is without any toxic potential even at the dose of 2000mg/kg in animals equivalent to 22.4g for human being. This dose in human being is 32 fold in comparison to normal human dose 0.7g per day. Mr. Ravi M M.Sc (Medical Pharmacology) Research Officer Pharmacology and Toxicology Lab Dr.B. Ravishankar M.Sc (Med Pharmacology)., Ph.D Director and Professor or Exptl Medicine SDM Centre for Research in Ayurveda and Allied Sciences Udupi Karnataka State 4
5 Acute oral toxicity study of test drug Makardhwaj Rasayan Tablet on rats Date of experiment : Acclimatization of animals : 7 days Date of treatment : End of experiment : Observation period : 14 days Regulatory guidelines followed : OECD test guideline No. 425 IAEC approved number : IAEC-12/11-SDMCRA SP/05 5
6 2. Materials methods: 2.1 Details of test formulation: 1. Name of the test formulation : Makardhwaj Rasayan Tablet Makardhwaj Rasayan Tablet- Information about name and quantity of the ingredients Ingredients name Botanical name Part or form Book Ref Quantity used 1. Makardhwaj Powder B.B.R mg 2. Rasasindur ---- Powder B.B.R mg 3. Mallasindur Powder B.B.R mg 4. Jatiphal Myristica fragrans Fruit A.P.I. 20 mg 5. Javantri Myristica fragrans Aerial Part A.P.I. 10 mg 6. Lavang Syzigium aromaticum Flower Bud A.P.I. 10 mg 7. Baras Karpur Cinnamomum camphora Crystal A.P.I mg 8. Swet Marich Piper nigrum Fruit A.P.I. 10 mg 9. Amber --- Masses A.B mg 10.Kesar Crocus sativus Style & Stigma A.P.I mg 11.Excipients Q.S. 12.Colour: Sunset Yellow -- Q.S. FCF Bhavana 1. Nagarvel Pan Rasa Piper betel Leaf A.P.I. Q.S. 2. Batch number : MTA01 ( Trial batch for product permission and mfg. Licence) 3. Manufacturing date : December Expiry date : November Storage condition : Cool and dry place 6. General use : Energy Tablet for Vigour and Vitality 7. CAS number : APPLIED 9. Country of origin : India 10. Manufacturer s name : VIRGO UAP Pharma Pvt.Ltd. Mahagujarat Ind.Estate Plot no. 423/ 98-B, Sarkhej - Bavala highway, Vill - MORAIYA, Ta - Sanand Dist - AHMEDABAD (GUJARAT) 6
7 2.2- TEST CONDITIONS 1. Animal species : Rats 2. Strain : Wistar albino 3. Source : Animal house attached to SDM Research centre, SDM Ayurveda College Udyavara 4. Selection : A total of 5 healthy either sex of body weight g Rats were selected according to AOT software. 5. Acclimatization period : All the selected animals were kept under acclimatization For 7 days before dosing. 7. Numbering and identification : The animal were marked with saturated Picric acid solution in water for proper identification. The marking within the cages is as follows. Animal Marking number 1 Head 2 Neck 3 Middle of the back 4 Base of the tail 5 No mark 7
8 The group number, animal number and sex of the animal were identified with the help of cage cards, as presented in following table. Sl. no Identification of animals Desired dose (according to AOT) Body weight (grams ) Calculated dose (ml) 1 Head 175mg/kg ml 2 Neck 550mg/kg ml 3 Back 2000mg/kg ml 4 Base of the tail 2000mg/kg ml 5 No mark 2000mg/kg ml Husbandry condition: 1. Housing : Rats were housed in each cage of poly propylene with stainless steel top grill. The dry husk was used as bedding material and was changed every morning. 2. Environment : The animal were exposed to 12 hours light and 12 hours dark cycle with The relative humidity 50 to 70 % and the ambient temperature was 22 ± 03 c. 3. Diet : Amruth brand rat pellete feed supplied by Pranav Agro Ltd, was provided throughout the study period except on previous night of dosing i.e(overnight) fasting before dosing. The drinking water was given ad libitum Propylene bottles with stainless steel sipper tube 8
9 2.4 Preparation of Test formulation for administration: 1. Test drug : Makardhwaj Rasayan Tablet 2. Vehicle : Gum acacia 3. Dose preparation: The test formulation supplied by sponsor was made in to Fine suspension in vehicle with suitable concentration All the animal were dosed constant dose volume (1 ml/ 100g body weight) 175mg/kg, 550mg/kg, 2000mg/kg 4. Schedule : single dose per animal a) Administration : The test formulation was administered through oral route at different dose levels to respective animals through oral feeding needle on to disposable syringe b) Dose fixation : According to the AOT Software. C) Route : oral d) Dose : 175mg/kg, 550mg/kg, 2000mg/kg test substance e) Dose volume : 1ml/100g animal 3. Observation: 3.1 Examination of Physical and Behavioural changes : The animal was observed continuously for 4 hours after the dosing. The careful cage side observation was done without disturbing the animal attention and at the end of the every hour the animal were individually exposed to open arena for recording the behavioural changes like increased or decreased motor activity, convulsions, straub s reaction, muscle spasm, catatonia, spasticity, ophisthotonus, hyperesthesia, muscle relaxation, anaesthesia, arching and rolling, lacrimation, salivation, diarrhoea, writhing, mode of respiration, changes in skin colour etc. exitus, CNS depression hypo activity, passivity, relaxation, ataxia, narcosis, etc. 9
10 3.2 Mortality: All the animals were observed at ½, 1, 2, 3, 4, 24 h, 48 h after dosing and there daily once for mortality during the entire period of the study (i.e.14 days). after 4. RESULT: 4.1 Physical and behavioural examination: There were no Physical and Behavioural changes-(except mild increase in motor activity and irritability were seen in animals dosed 550mg/kg and 2000mg/kg) in all the treated animals on day one at ½, 1,2,3,4 hours intervals after dosing and there after once daily for 14 consecutive days. Thus the data obtained from the study on single dose administration of Makardhwaj Rasayan Tablet oral administration up to 14 days of observation period does not result in any physical and behavioural changes. 4.2 Mortality: All the animals belonging to the treated group were survived throughout the 14 days observation period after dosing. 10
11 Conclusion: The test drug did not produce any mortality up to the dose of 2000mg/kg per oral which is equivalent to 22.4g total dose for a human being weighing 70 kg man. At the dose level studied the drug also did not produce any observable toxic effect except for mild irritation in animal in dose550mg/kg and 2000mg/kg and thus it could be concluded that the test drug is without any toxic potential even at the dose of 2000mg/kg in animals equivalent to 22.4g for human being. Dr. B. Ravishankar 11
12 Pharmacology Laboratory SDM Centre for research in Ayurveda & allied sciences, Kuthpadi, Udupi PRO FORMA FOR RECORDING SIGNS AND SYMPTOMS DURING ACUTE TOXICITY STUDIES Group: 175mg /kg Date: 13/01/12 Dose: 1.25ml Animal: Rat 1(250g) Route: Oral Drug: Makardhwaj Rasayan Tablet SIGNS & SYMPTOMS Basal 30min 1h 2h 3h 4h 24h 48h General impression N N N N N N N N Increased motor activity Convulsion: Tonic Clonic Straubs reaction Muscle spasm Catatonia Opisthotonus Hyperaesthesia Decreased motor activity Muscle relaxation Anaesthesia Arching and rolling Lacrimation Diarrhoea Writhing Salivation Viscid Watery Respiration Stimulation Depression Failure Skin colour Blanching Cyanosis Vasodilatation Grip strength(kg)-mean N N N N N N N N Visual placing response N N N N N N N N Tail pinch response N N N N N N N N Auditory response N N N N N N N N mucus membrane N N N N N N N N Piloerection Experiment conducted by: Head of the lab (Director): N: Normal 12
13 Pharmacology Laboratory SDM Centre for research in Ayurveda & allied sciences, Kuthpadi, Udupi PRO FORMA FOR RECORDING SIGNS AND SYMPTOMS DURING ACUTE TOXICITY STUDIES Group: 550mg/kg Date: 16/01/12 Dose: 1.375ml Animal: Rat-2(175g) Route: Oral Drug: Makardhwaj Rasayan Tablet SIGNS & SYMPTOMS Basal 1/2 1h 2h 3h 4h 24h 48h General impression N N Active Active Active N N N Increased motor activity Convulsion: Tonic Clonic Straubs reaction Muscle spasm Catatonia Opisthotonus Hyperaesthesia Decreased motor activity Muscle relaxation Anaesthesia Arching and rolling Lacrimation Diarrhoea Writhing Salivation Viscid Watery Respiration Stimulation Depression Failure Skin colour Blanching Cyanosis Vasodilatation Grip strength(kg)-mean N N N N N N N N Visual placing response N N N N N N N N Tail pinch response N N N N N N N N Auditory response N N N N N N N N mucus membrane N N N N N N N N Piloerection Experiment conducted by: Head of the lab (Director): N: Normal 13
14 Pharmacology Laboratory SDM Centre for research in Ayurveda & allied sciences, Kuthpadi, Udupi PRO FORMA FOR RECORDING SIGNS AND SYMPTOMS DURING ACUTE TOXICITY STUDIES Group: 2000mg/kg Date: 19/01/12 Dose: 5.7ml Animal: Rat-3(200g) Route: Oral Drug: Makardhwaj Rasayan Tablet SIGNS & SYMPTOMS Basal 1/2 1h 2h 3h 4h 24h 48h General impression N Active Active Active active N N N Increased motor activity Convulsion: Tonic Clonic Straubs reaction Muscle spasm Catatonia Opisthotonus Hyperaesthesia Decreased motor activity Muscle relaxation Anaesthesia Arching and rolling Lacrimation Diarrhoea Writhing Salivation Viscid Watery Respiration Stimulation Depression Failure Skin colour Blanching Cyanosis Vasodilatation Grip strength(kg)-mean N N N N N N N N Visual placing response N N N N N N N N Tail pinch response N N N N N N N N Auditory response N N N N N N N N mucus membrane N N N N N N N N Piloerection Experiment conducted by: Head of the lab (Director): N: Normal 14
15 Pharmacology Laboratory SDM Centre for research in Ayurveda & allied sciences, Kuthpadi, Udupi PRO FORMA FOR RECORDING SIGNS AND SYMPTOMS DURING ACUTE TOXICITY STUDIES Group: 2000mg/kg Date: 21/01/12 Dose: 4.5ml Animal: Rat-4(160g) Route: Oral Drug: Makardhwaj Rasayan Tablet SIGNS & SYMPTOMS Basal 30 min 1h 2h 3h 4h 24h 48h General impression N N active Irritated N N N N Increased motor activity Convulsion: Tonic Clonic Straubs reaction Muscle spasm Catatonia Opisthotonus Hyperaesthesia Decreased motor activity Muscle relaxation Anaesthesia Arching and rolling Lacrimation Diarrhoea Writhing Salivation Viscid Watery Respiration Stimulation Depression Failure Skin colour Blanching Cyanosis Vasodilatation Grip strength(kg)-mean N N N N N N N N Visual placing response N N N N N N N N Tail pinch response N N N N N N N N Auditory response N N N N N N N N mucus membrane N N N N N N N N Piloerection Experiment conducted by: Head of the lab (Director): N: Normal 15
16 Pharmacology Laboratory SDM Centre for research in Ayurveda & allied sciences, Kuthpadi, Udupi PRO FORMA FOR RECORDING SIGNS AND SYMPTOMS DURING ACUTE TOXICITY STUDIES Group: 2000mg/kg Date: 23/01/12 Dose: 4.5ml Animal: Rat-5(160g) Route: Oral Drug: Makardhwaj Rasayan Tablet SIGNS & SYMPTOMS Basal 1/2 1h 2h 3h 4h 24h 48h General impression N N Active Active N N N N Increased motor activity Convulsion: Tonic Clonic Straubs reaction Muscle spasm Catatonia Opisthotonus Hyperaesthesia Decreased motor activity Muscle relaxation Anaesthesia Arching and rolling Lacrimation Diarrhoea Writhing Salivation Viscid Watery Respiration Stimulation Depression Failure Skin colour Blanching Cyanosis Vasodilatation Grip strength(kg)-mean N N N N N N N N Visual placing response N N N N N N N N Tail pinch response N N N N N N N N Auditory response N N N N N N N N mucus membrane N N N N N N N N Piloerection Experiment conducted by: Head of the lab (Director): N: Normal 16
17 Rat No.1 Time of drug administration Time interval (min) Exitus Hypo activity Passivity Relaxation Ataxia Narcosis Ptosis Exophthalmos es Hyperactivity Irritability Stereotypy Tremors Convulsion Straub tail Analgesia Others Pharmacology Laboratory SDM Centre for research in Ayurveda & allied sciences, Kuthpadi, Udupi Pro forma for assessing Gross behaviour Drug : Makardhwaj Rasayan Tablet Date : 13/01/12 Group: 175mg/kg Route: Oral Animal: Rat-1 (125) Study: Acute oral toxicity CNS Depression ANS CNS Stimulation Basal h 48 h Experiment conducted by: Head of the lab (Director): 17
18 Rat No5 Time of drug administration Time interval (min) Exitus Hypo activity Passivity Relaxation Ataxia Narcosis Ptosis Exophthalmo ses Hyperactivit y Irritability Stereotypy Tremors Convulsion Straub tail Analgesia Others Pharmacology Laboratory SDM Centre for research in Ayurveda & allied sciences, Kuthpadi, Udupi Pro forma for assessing Gross behaviour Drug : Makardhwaj Rasayan Tablet Date : 16/01/12 Group : 550mg/kg Route: Oral Animal: Rat-2(175g) Study: Acute oral toxicity CNS Depression ANS CNS Stimulation Basal h h Experiment conducted by: Head of the lab (Director): 18
19 Rat No.4 Time of drug administration Time interval (min) Exitus Hypo activity Passivity Relaxation Ataxia Narcosis Ptosis Exophthalmos es Hyperactivity Irritability Stereotypy Tremors Convulsion Straub tail Analgesia Others Pharmacology Laboratory SDM Centre for research in Ayurveda & allied sciences, Kuthpadi, Udupi Pro forma for assessing Gross behaviour Drug : Makarandhwaj Rasayan Tablet Date : 19/01/12 Group : 550mg/kg Route: Oral Animal: Rat-2(175g) Study: Acute oral toxicity CNS Depression ANS CNS Stimulation Basal h 48 h Experiment conducted by: Head of the lab (Director): 19
20 Rat No.3 Time of drug administration Time interval (min) Exitus Hypo activity Passivity Relaxation Ataxia Narcosis Ptosis Exophthalmos es Hyperactivity Irritability Stereotypy Tremors Convulsion Straub tail Analgesia Others Pharmacology Laboratory SDM Centre for research in Ayurveda & allied sciences, Kuthpadi, Udupi Pro forma for assessing Gross behaviour Drug : Makarandhwaj Rasayan Tablet Date : 21/01/12 Group : 550mg/kg Route: Oral Animal: Rat-2(175g) Study: Acute oral toxicity CNS Depression ANS CNS Stimulation Basal h 48 h Experiment conducted by: Head of the lab (Director): 20
21 Rat No.2 Time of drug administration Time interval (min) Exitus Hypo activity Passivity Relaxation Ataxia Narcosis Ptosis Exophthalmo ses Hyperactivit y Irritability Stereotypy Tremors Convulsion Straub tail Analgesia Others Pharmacology Laboratory SDM Centre for research in Ayurveda & allied sciences, Kuthpadi, Udupi Proforma for assessing Gross behaviour Drug: Makardhwaj Rasayan Tablet Date : 23/01/12 Group: 2000mg/kg Route: Oral Animal: Rat -5 (160g) Study: Acute oral toxicity CNS Depression ANS CNS Stimulation Basal h 48 h Experiment conducted by: Head of the lab (Director): 21
Acute Oral Toxicity Study on
Acute Oral Toxicity Study on SOBEREX CAPSULE OF Sponsor Study Centre: VIRGO UAP PHARMA PVT.LTD. PHARMACOLOGY LABORATORY MAHAGUJARAT IND.ESTATE, SDM CENRE FOR RESEARCH IN PLOT NO. 423/98-B. AYURVEDA AND
More informationFinal Report. Acute oral toxicity study in Wistar rats. Mr. S. Haribabu, B Tech (Biotech), MSc
Study Title Test Item Study Director Sponsor Study Monitor Test Facility Acute oral toxicity study in Wistar rats Nualgi Nano Nutrients Mr. S. Haribabu, B Tech (Biotech), MSc Nualgi Nano Biotech Co 651,
More informationFinal Report. Acute dermal toxicity study in Wistar rats. Mr. M. Vasanthan, M Tech (Biotech)
Study Title Test Item Study Director Sponsor Study Monitor Test Facility Acute dermal toxicity study in Wistar rats Nualgi Nano Nutrients Mr. M. Vasanthan, M Tech (Biotech) Nualgi Nano Biotech Co 651,
More informationAcute Toxicity Profiling of Siddha Drug Oma Kudineer in Wistar Rats
Human Journals Research Article September 2017 Vol.:10, Issue:2 All rights are reserved by Dr. D. S. LAVANYA et al. Acute Toxicity Profiling of Siddha Drug Oma Kudineer in Wistar Rats Keywords: Oma kudineer,
More informationSHRIRAM INSTITUTE FOR INDUSTRIAL RESEARCH. ACUTE ORAL TOXICITY STUDY IN RATS WITH Cry 1 C a 1 PROTEIN
ACUTE ORAL TOXICITY STUDY IN RATS WITH Cry 1 C a 1 PROTEIN REPORT FOR METAHELIX LIFE SCIENCES PVT. LTD., PLOT NO.-3, KIADB 4 TH PHASE, BOMMASANDRA, BANGALORE-500 099, INDIA. GUIDELINES DBT Guidelines TEST
More informationAn Oral Acute Toxicity Study of Extracts from Salvia Splendens (Scarlet Sage) As Per OECD Guidelines 423
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationPharmacological study
PHARMACOLOGICAL STUDY Pharmacology is one of the cornerstones of the drug discovery process. The medicinal chemist may create the candidate compound, but the pharmacologist is the one who tests it for
More informationMeena R et al / Int. J. Res. Ayurveda Pharm. 6(6), Nov - Dec Research Article.
Research Article www.ijrap.net ACUTE TOXICITY STUDY OF A SIDDHA FORMULATION KANDHAGA RASAYANAM IN RATS Meena R 1 * and Ramaswamy R.S 2 1 Ph.D Scholar, Department of Sirappu Maruthuvam, National Institute
More informationFINAL REPORT STUDY TITLE. EVALUATION OF APHRODISIAC ACTIVITY OF VigRx IN MALE ALBINO WISTAR RATS. Report No.: R401.
FINAL REPORT STUDY TITLE EVALUATION OF APHRODISIAC ACTIVITY OF IN MALE ALBINO WISTAR RATS STUDY DIRECTOR Dr. Amit A, Ph.D. SPONSOR AIBMR Life Sciences, Inc. 4117, South Meridian, Puyallup, WA 98373 CONTENTS
More informationSTUDY ON ACUTE TOXICITY OF SIDDHA FORMULATION UPPU CHENDURAM - II IN WISTAR RATS
Siddha Papers 2018 (13) (2) RESEARCH ARTICLE https://www.siddhapapers.com STUDY ON ACUTE TOXICITY OF SIDDHA FORMULATION UPPU CHENDURAM - II IN WISTAR RATS Bhuvaneshwari T* 1, Subash Chandran G 2, Manoharan
More informationScholars Research Library
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2010, 2(5): 358-362 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationAcute and subacute oral toxicity study of Rasa chenduram
International Journal of Advanced Research in Biological Sciences ISSN: 2348-8069 www.ijarbs.com DOI: 10.22192/ijarbs Coden: IJARQG(USA) Volume 4, Issue 11-2017 Research Article DOI: http://dx.doi.org/10.22192/ijarbs.2017.04.11.004
More informationPRODUCT STUDY TITLE DATA REQUIREMENT AUTHOR STUDY COMPLETED ON PERFORMING LABORATORY LABORATORY STUDY NUMBER
Product Safety Laboratories 2394 Highway 130 Dayton, NJ 08810 Tel: 732.438.5100 Fax: 732.355.3275 e-mail: PSL@productsafetylabs.com PRODUCT Stalosan F STUDY TITLE Acute Dermal Toxicity Study in Rats -
More informationSafety Data Sheet Gabapentin Tablet
EMERGENCY OVERVIEW s contain Gabapentin and excipients generally considered to be non- toxic and non-hazardous in small quantities and under conditions of normal occupational exposure. Section 1. Identification
More informationAcute Toxicity Study of Abhraka Bhasma A Behavioral Observation
Human Journals Research Article September 2015 Vol.:1, Issue:3 All rights are reserved by Pankaj Rai et al. Acute Toxicity Study of Abhraka Bhasma A Behavioral Observation Keywords: Abhraka bhasma, acute
More informationSHRIRAM INSTITUTE FOR INDUSTRIAL RESEARCH
IN RATS SUB CHRONIC ORAL TOXICITY WITH NHH 44 Bt-COTTON SEEDS Report for: UNIVERSITY OF AGRICULTURAL SCIENCES AGRICULTURAL RESEARCH STATION DHARWAD-580007 KARNATAKA Guidelines: DBT, Guidelines for Toxicity
More informationSummary of product characteristics As per Annexure C. SUMMARY OF PRODUCT CHARACTERISTICS Doc. No. SPC/71108 Ver.1
Summary of product characteristics As per Annexure C SUMMARY OF PRODUCT CHARACTERISTICS Doc. No. SPC/71108 Ver.1 1. NAME OF THE MEDICINAL PRODUCT. ANNEXURE C to MODULE I Measles, Mumps & Rubella Vaccine
More informationAnalgesic Activity of Sathikkai Podi- a Siddha Drug
Research Article Analgesic Activity of Sathikkai Podi- a Siddha Drug K. Kanagavalli 1, P. Kavitha 2, J. Anbu 3, P. Sathiya Rajeswaran 4 and P. Parthiban 5 1 UG Maruthuvam Department. 2 PG Scholar final
More informationMB Research Laboratories
MB Research Laboratories 1765 Wentz Road P.O. Box 178 Spinnerstown, PA 18968 phone (215) 536-4110 fax (215) 536-1816 Study Title : Single Dose Oral Toxicity in Rats Test Article : ZEOLITE PURE, Lot/Batch#
More informationINTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE
INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE EVALUATION OF ACUTE AND SUB ACUTE TOXICIY STUDY OF KANDANGKATHIRI KIRUTHAM (GHEE OF SOLANUM XANTHOCARPUM) IN ANIMAL MODEL. DR. S. CHITRA
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER 250 mg film-coated tablets. 500 mg film-coated tablets. 750 mg film-coated tablets. 1000 mg film-coated tablets. Levetiracetam
More informationSulfamethoxazole/Trimethoprim 400mg/80mg Tablets (Micro Labs Ltd), HA598. WHOPAR part 5 July 2017 LABELLING
LABELLING PARTICULARS TO APPEAR ON THE OUTER PACKAGING Label/HDPE BOTTLE 1. NAME OF THE MEDICINAL PRODUCT Trimethoprim and Sulfamethoxazole Tablets BP 80 mg/400 mg 1 2. STATEMENT OF ACTIVE SUBSTANCE Each
More informationACUTE AND SUB ACUTE TOXICITY STUDIES OF HERBO- METALLIC FORMULATION VANGA CHENDURAM
Research Article International Ayurvedic Medical Journal ISSN:2320 5091 ACUTE AND SUB ACUTE TOXICITY STUDIES OF HERBO- METALLIC FORMULATION VANGA CHENDURAM R. Kayal vizhi, 1 P.Muralidharan 2 S.Kaniraja,
More informationAcute Oral Toxicity Study in Rats with Argentyn 23 (EPA/OECD Guidelines) Study Title. Monica M. Vegarra, BS. Sponsor
Note: This study was done using our Professional strength 23 ppm product (Argentyn 23), therefore making Sovereign Silver at 10 ppm, 2.3 times safer. Conclusion on page 6 shows the product to be non-toxic
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET Page 1 of 6 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Closerine * Cycloserine 250 mg capsules Read all of this leaflet carefully before you start taking this medicine
More informationAN ACUTE ORAL TOXICITY STUDY IN RATS WITH ADVANTRA Z
AN ACUTE ORAL TOXICITY STUDY IN RATS WITH ADVANTRA Z AMENDED FINAL REPORT Author Deborah A Douds, M.S. Original Study Completion Date July 8, 1997 Amended Study Completion Date November 19, 1997 Performing
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET Page 1 of 7 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Cycloserine Capsules Ph. Int. 250 mg 1 Cycloserine Read all of this leaflet carefully before you start taking
More informationACUTE TOXICITY STUDY FOR CENTELLA ASIATICA WHOLE PLANT POWDER
ACUTE TOXICITY STUDY FOR CENTELLA ASIATICA WHOLE PLANT POWDER Shirish S. Pingale Gramonnati Mandal s Arts, Commerce and Science College, Narayangaon, Pune, Pin - 410 504, Maharashtra, India. (Affiliated
More informationInternational Journal of Medicine and Health Profession Research
Research Article ISSN: 2394 7403 International Journal of Medicine and Health Profession Research Journal home page: www.ijmhpr.com TOXICITY STUDY OF VAIVILANGAM CHOORANAM E. M. Manikgantan* 1 and R. Pattarayan
More informationPublic Assessment Report. Mebeverine hydrochloride 50mg/5ml Oral Suspension. (Mebeverine hydrochloride) UK Licence No: PL 44710/0024
Public Assessment Report Mebeverine hydrochloride 50mg/5ml Oral Suspension (Mebeverine hydrochloride) UK Licence No: PL 44710/0024 Kinedexe UK Limited 1 LAY SUMMARY Mebeverine hydrochloride 50mg/5ml Oral
More informationOECD GUIDELINE FOR TESTING OF CHEMICALS
OECD/OCDE 420 Adopted: 17 th December 2001 OECD GUIDELINE FOR TESTING OF CHEMICALS Acute Oral Toxicity Fixed Dose Procedure INTRODUCTION 1. OECD Guidelines for the Testing of Chemicals are periodically
More informationIngredient Listing Qty. Unit NDC # Supplier. q.s. to ml
12/20/2018; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier, USP 10 MU Sucrose, NF 23.00 g Propylene Glycol, USP 7.0 ml Medisca Oral Mix (Flavored Suspending Vehicle) 50.0 ml Medisca
More informationMATERIAL SAFETY DATA SHEET
MATERIAL SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY Material Manufacturer Distributor Imipramine Hydrochloride Tablets USP 10 mg, 25mg and 50mg Lupin Limited Goa 403 722 INDIA
More informationDAEHSAN BIOTECH PRIVATE LIMITED Industrial Growth Centre, Assam Industrial Development Corporation, Balipara, Sonitpur, Assam.
DAEHSAN BIOTECH PRIVATE LIMITED Industrial Growth Centre, Assam Industrial Development Corporation, Balipara, Sonitpur, Assam. Pin: 784105 1. Name of the product : DXN GANOCELIUM (GL) 2. Composition :
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET Page 1 of 7 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Cycloserine Capsules USP 250 mg 1 Cycloserine Read all of this leaflet carefully before you start taking this
More informationArtemether 20mg/lumefantrine 120mg WHOPAR part 5 12/2011 Dispersible tablets (Novartis Pharma AG), MA069 LABELLING. Page 1 of 6
LABELLING Page 1 of 6 PARTICULARS TO APPEAR ON THE OUTER PACKAGE CARTON OF UNIT PACK 1. NAME OF THE MEDICINAL PRODUCT Coartem Dispersible Artemether/Lumefantrine 2. STATEMENT OF ACTIVE SUBSTANCE(S) Artemether
More informationOECD/OCDE 245 Adopted: 9 October 2017
Adopted: 9 October 2017 OECD GUIDELINE FOR THE TESTING OF CHEMICALS HONEY BEE (APIS MELLIFERA L.), CHRONIC ORAL TOXICITY TEST (10-DAY FEEDING) INTRODUCTION 1. This Test Guideline describes a chronic oral
More informationWhat is the most important information I should know about levetiracetam tablets?
MEDICATION GUIDE Levetiracetam Tablets USP (LEE-ve-tye-RA-se-tam) Read this Medication Guide before you start taking levetiracetam tablets and each time you get a refill. There may be new information.
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationLABELING - SKIN OF PRODUCT Arun. N 1 Kadibagil vinay R 2 Ganti basavaraj Y 3 PG Scholar,
Review Article International Ayurvedic Medical Journal ISSN:2320 5091 LABELING - SKIN OF PRODUCT Arun. N 1 Kadibagil vinay R 2 Ganti basavaraj Y 3 PG Scholar, Associate Professor, Associate Professor &
More informationC.16. HONEYBEES - AC UTE ORAL TOXICITY TEST. This acute toxicity test method is a replicate of the OECD TG 213 (1998).
C.16. HONEYBEES - AC UTE ORAL TOXICITY TEST 1. METHOD This acute toxicity test method is a replicate of the OECD TG 213 (1998). 1.1 INTRODUCTION This toxicity test is a laboratory method, designed to assess
More informationLIQUID PREPARATIONS FOR ORAL USE. Final text for addition to The International Pharmacopoeia (November 2007)
November 2007 LIQUID PREPARATIONS FOR ORAL USE Final text for addition to The International Pharmacopoeia (November 2007) This monograph was adopted at the Forty-second WHO Expert Committee on Specifications
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Radicava GENERIC NAME edaravone MANUFACTURER MT Pharma America, Inc. DATE OF APPROVAL May 5, 2017 PRODUCT LAUNCH DATE May 5, 2017 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review
More informationTOOTH WHITENING. Copyright 2017 Dr Krystyna
TOOTH WHITENING What is tooth whitening? Tooth whitening can be a very effective way of lightening the natural colour of your teeth without removing any of the tooth surface. It cannot make a complete
More informationIMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION Pr BACLOFEN Baclofen Tablets 10 mg and 20 mg This leaflet is part III of a three-part "Product Monograph" published when BACLOFEN was approved for sale in Canada and is designed
More informationPhysiological normal values (Depends on age, strain, health status, type of anesthesia, etc.)
UBC Animal Care Guidelines This SOP will be used for: Inhalational anesthesia SOP: ACC-01-2017 Rodent Anesthesia Injectable anesthesia Submitted by: Shelly McErlane both inhalational and injectable anesthesia
More informationAcute and sub-acute (28-days) oral toxicity studies of Eraippu noi chooranam
International Journal of Advanced Research in Biological Sciences ISSN: 2348-8069 www.ijarbs.com Volume 3, Issue 6-2016 Research Article Acute and sub-acute (28-days) oral toxicity studies of Eraippu noi
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Meptid 100 mg/ml Solution for Injection. Meptazinol
PACKAGE LEAFLET: INFORMATION FOR THE USER Meptid 100 mg/ml Solution for Injection Meptazinol Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need
More informationLITHIUM PHOSPHATE SAFETY DATA SHEET DATE OF LAST REVISION: 07/13/15. Section 1: Identification
Section 1: Identification LITHIUM PHOSPHATE DATE OF LAST REVISION: 07/13/15 Product Name: Lithium Phosphate CAS Number: 10377-52-3 / EC Number: 233-823-0 Company: Angstrom Sciences, Inc. 40 South Linden
More informationPacificBeam SHELLIII/PB-SHELL3: ACUTE DERMAL IRRITATION IN THE RABBIT PROJECT NUMBER: 2533/0014 AUTHOR:
PAGE 1 OF 14 PAGES PacificBeam SHELLIII/PB-SHELL3: ACUTE DERMAL IRRITATION IN THE RABBIT PROJECT NUMBER: 2533/0014 AUTHOR: A Sanders STUDY SPONSOR: M.I.C.(Medical Intelligence Corporation) Co., Ltd. 2-2-15
More informationPack Size: 90,100, 500 and 1000 Tablets per bottle. Strength: 150mg, 200mg and 250mg Pack Size: 60, 90 and 500 Tablets per bottle Revision No.
EMERGENCY OVERVIEW Each Lamotrigine tablets intended for oral administration contains Lamotrigine and excipients generally considered to be non- toxic and non-hazardous in small quantities and under conditions
More informationWithdrawal.
Withdrawal Shamim Nejad, MD Director, Adult Burns & Trauma Psychiatry Division of Psychiatry and Medicine Medical Director, Addiction Consultation Team MGH Center for Addiction Medicine Massachusetts General
More informationPANCHAGAVYA KRISHIMATE AGRO AND DAIRY PVT LTD. No. 1176, 12th B Main, Hal 2nd Stage, Indira Nagar, Bengaluru , Karnataka, India
PANCHAGAVYA KRISHIMATE AGRO AND DAIRY PVT LTD [ A venture of Sri Sai Agro Implements ] No. 1176, 12th B Main, Hal 2nd Stage, Indira Nagar, Bengaluru - 560008, Karnataka, India Ph: +91-80-25216158, M: +91-9448059909,
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 02 Sep 2018 23:38:24 GMT) CTRI Number Last Modified On 05/02/2015 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationAssessment of chlorpyrifos and lead acetate combination on neurobehavioral aspects in Wistar rats after subchronic dietary exposure
Assessment of chlorpyrifos and lead acetate combination on neurobehavioral aspects in Wistar rats after subchronic dietary exposure 1 H Krishna*, 2 AV Ramachandran 1 Dhirubhai Ambani Life Sciences Centre,
More informationFor Investigational Use Only. Hypoxyprobe -1. [Pimonidazole Hydrochloride] [CAS# ]
Hypoxyprobe -1 [Pimonidazole Hydrochloride] [CAS# 70132-50-2] An Investigational New Drug for the detection of tissue hypoxia Material Safety Data Sheet Reviewed August 24, 2016 1 Material Safety Data
More informationAbstract. Research Article. Keywords: Tagara, Jatamansi, Hypnotic and sedative activity, Anti anxiety, Anti depressant.
2015; 4(3): 147-151 Online at: www.phytopharmajournal.com Research Article ISSN 2230-480X JPHYTO 2015; 4(3): 147-151 May- June 2015, All rights reserved Toolika E Ravi M Department of Pharmacology & Sciences,
More informationLamivudine Tablets 150 mg (Macleods Pharmaceuticals Ltd), HA424. WHOPAR Part 5 05/2011, version 1.0 LABELLING. Page 1 of 8
LABELLING Page 1 of 8 PARTICULARS TO APPEAR ON THE OUTER PACKAGING Bottle carton label 1. NAME OF THE MEDICINAL PRODUCT Lamivudine 150 mg Tablets * 2. STATEMENT OF ACTIVE SUBSTANCE Each film-coated tablet
More informationStrength: 60 mg and 120 mg Pack Size: 90 and 100 Tablets per bottle Revision No.: 00
EMERGENCY OVERVIEW Each Nateglinide Tablets intended for oral administration contains Nateglinide and excipients generally considered to be non- toxic and non-hazardous in small quantities and under conditions
More informationPage 1132
Page 1131 Page 1132 Page 1133 Page 1134 Page 1135 Huntingdon Life Sciences 03-6140 Page 6. Final Report TABLE OF CONTENTS Page 1136 COVER PAGE...1 GLP STATEMENT...2 SIGNATURE PAGE...3 QUALITY ASSURANCE
More informationLakshmi Kantham T et al / Int. J. Res. Ayurveda Pharm. 8 (Suppl 2), Research Article.
Research Article www.ijrap.net ACUTE, SUB-ACUTE (8-DAYS), AND SUB-CHRONIC (90-DAYS) ORAL TOXICITY STUDIES OF NANDHI MEZHUGU Lakshmi Kantham T 1 *, Ganapathy G, Suba V, Srinivasan M. R, Geetha A 5 Lecturer,
More informationEFFECT OF CONVULVULUS PLURICAULIS CHOISY. ON LEARNING BEHAVIOUR AND MEMORY ENHANCEMENT ACTIVITY IN RODENTS
EFFECT OF CONVULVULUS PLURICAULIS CHOISY. ON LEARNING BEHAVIOUR AND MEMORY ENHANCEMENT ACTIVITY IN RODENTS ALOK NAHATA* AND V.K. DIXIT Natural Product Research Laboratory, Department of Pharmaceutical
More informationExtended therapeutic validation of an anti-mc4 receptor antibody in an animal model of anorexia nervosa
Extended therapeutic validation of an anti-mc4 receptor antibody in an animal model of anorexia nervosa (project no. 04-12B) Authors Guus Akkermans, Martien Kas Preliminary data report Introduction In
More informationAcute and Sub-Acute Toxicity Study of Compound Siddha Drug Lagu Seena Chooranam for the Management of Scabies
Human Journals Research Article September 2015 Vol.:4, Issue:2 All rights are reserved by A.Silambarasan et al. Acute and Sub-Acute Toxicity Study of Compound Siddha Drug Lagu Seena Chooranam for the Management
More informationStandard Operating Procedure
1.0 Purpose: 1.1 Relaxation, dissection, weighing and fixation of heart for histological analysis. Changes in heart weight and wall thickness are linked to cardiovascular phenotypes. This protocol describes
More informationDocument Details. Patient Group Direction
Document Details Title Patient Group Direction (PGD) Salbutamol Aerosol Inhaler and salbutamol Nebulised Solution Trust Ref No 1569-34313 Local Ref (optional) Main points the document Treatment of acute
More informationLubriTose Mannitol Michael Crowley, Director of R&D, Excipients
LubriTose Mannitol Michael Crowley, Director of R&D, Excipients Introduction Michael Crowley Director of R&D Excipients 158 St. Highway 320 Norwich, NY 13815 PH 315-802-5970 Michael.Crowley@Kerry.com 2
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET Page 1 of 6 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER 1 ethambutol hydrochloride Read all of this leaflet carefully before your child starts taking this medicine
More informationDocument Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the
Document Details Title Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No 1506-41174 Local Ref (optional) Main points the Active immunisation against infection caused by Hepatitis
More informationMonograph. Addendum 1. Ferric phosphate. Ecotoxicology. Rapporteur Member State: Germany. 26 May 2000
11097/ECCO/BBA/00 Addendum 1 to draft assessment report (6613/ECCO/PSD/99) Monograph Addendum 1 26 May 2000 Ferric phosphate Ecotoxicology Rapporteur Member State: Germany 2/3 Addendum B.09.06 Effects
More informationCadila Healthcare Ltd. Ahmedabad, India. Sarkhej Bavla. N.H. 8A, Moraiya. Tal. Sanand. Dist. Ahmedabad State: Gujarat.
EMERGENCY OVERVIEW Etomidate Injection intended for Intravenous injection contains Etomidate and excipients generally considered to be non- toxic and non-hazardous in small quantities and under conditions
More informationC17H21NO3 HBr (4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11- methyl-6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol hydrobromide
EMERGENCY OVERVIEW Each Galantamine Tablet intended for oral administration contains galantamine hydrobromide equivalent to galantamine 4 mg or 8 mg or 12 mg and excipients considered non-toxic and nonhazardous
More informationPatient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationEntecavir Tablets USP
EMERGENCY OVERVIEW Each intended for oral administration contains Entecavir and excipients generally considered to be non- toxic and non-hazardous in small quantities and under conditions of normal occupational
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET Page 1 of 5 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Diethylcarbamazine Citrate Tablets 100 mg USP * (DEC Tablets) diethylcarbamazine citrate DIETHYLCARBAMAZINE
More informationIt does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.
Sevorane SEVOFLURANE Consumer Medicine Information What is in this leaflet? This leaflet answers some common questions about Sevorane It does not contain all the available information. It does not take
More informationSTABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS
Int. J. Chem. Sci.: 8(1), 2010, 405-414 STABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS V. L. NARASAIAH, T. KARTHIK KUMAR, D. SRINIVAS, K. SOWMYA, P. L. PRAVALLIKA and Sk. Md. MOBEEN
More informationPATIENT INFORMATION LEAFLET FOR TEXA 10 mg TABLETS AND TEXA SYRUP PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM:
SCHEDULING STATUS: S2 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: TEXA 10 mg (tablets) TEXA SYRUP (syrup) Read this entire leaflet carefully before you start taking TEXA. Keep this leaflet. You
More informatione-issn Toxicological Study of Rasamanikya by L.D. 50 Method Bhange Pankaj 1, Undale Vidya 2, Bhatambre Yogesh 3 and Bhange Pallavi 4 *
RESEARCH ARTICLE www.ijapc.com e-issn 2350-0204 Toxicological Study of Rasamanikya by L.D. 50 Method Bhange Pankaj 1, Undale Vidya 2, Bhatambre Yogesh 3 and Bhange Pallavi 4 * 1 Dept. of Agadtantra, DhanwantariAyurved
More informationStrength: 1.25/2.5/5/10mg. Pack Size: Bottles 30/90/100/500 Capsules Blisters 100 Capsules Revision No.: 02
EMERGENCY OVERVIEW Each Ramipril Capsules USP intended for oral administration contains Ramipril and excipients generally considered to be non- toxic and non-hazardous in small quantities and under conditions
More informationA. K. EYONG AND V. B. BRAIDE
GLOBAL JOURNAL OF MEDICAL SCIENCES VOL 8, NO. 1&2, 2009: 23-30 COPYRIGHT BACHUDO SCIENCE CO. LTD PRINTED IN NIGERIA. ISSN 1596-2911 www.globaljournalseries.com; Email: info@globaljournalseries.com EFFECTS
More informationSynergistic Anti-Depression Activity Evaluation of Different Composition of Volatile Oil of Eucalyptus and Neem Oil by Tail Suspension Model
Human Journals Research Article November 2015 Vol.:4, Issue:4 All rights are reserved by Kishu Tripathi et al. Synergistic Anti-Depression Activity Evaluation of Different Composition of Volatile Oil of
More informationFYTOCARE CHEMICALSPVT LTD SF NO 397 /3, MADUKKARAI MAIN ROAD, BODIPALAYAM VILLAGE, COIMBATORE MATERIAL SAFETY DATA SHEET : BROMADIOLONE 0.
MATERIAL SAFETY DATA SHEET : BROMADIOLONE 0.005 % RB 1.CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT ME MOLECULAR FORMULA SYNONYMS FYTOCARE CHEMICALSPVT LTD Bromadiolone 0.005 % RB C30H23BrO4 NONE
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Duraphat 5000 ppm Fluoride Toothpaste 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g of toothpaste contains 5 mg fluoride (as sodium fluoride),
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET Page 1 of 5 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Closerin * Cycloserine 250 mg capsules Read all of this leaflet carefully before you start taking this medicine
More informationMATERIAL SAFETY DATA SHEET
MATERIAL SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY Material Manufacturer Distributor Ramipril Capsules 1.25 mg, 2.5 mg, 5 mg and 10 mg Lupin Limited Mumbai 400 098 INDIA Lupin
More informationSAFETY DATA SHEET according to Regulation (EC) No. 1907/2006
SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006 AXCELA Version 1.1 / EN Revision Date 19.08.2013 Print Date 23.09.2013 1. Identification of the substance/mixture and of the company/undertaking
More informationMaterial Safety Data Sheet According to ISO Page 1 of 5 ; 1. IDENTIFICATION OF SUBSTANCE
According to ISO 11014-1 Page 1 of 5 ; 1. IDENTIFICATION OF SUBSTANCE Name: Manufacturer: Information Department: CAFFEINE INJECTION 10 mg/ml & Department of Pharmacy Duke University Medical Center Box
More informationMATERIAL SAFETY DATA SHEET
MATERIAL SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY Material Manufacturer Distributor Gatifloxacin Ophthalmic Solution 0.5% Lupin Limited Pithampur (M. P.), 454 775 India. Lupin
More informationNew Drugs Division. Frequently Asked Questions (FAQs) on Approval of new Phytopharmaceutical Drugs
Central Drugs Standard Control Organization Directorate General of Health Services Ministry of Health and Family Welfare Government of India New Drugs Division Frequently Asked Questions (FAQs) on Approval
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. SALAGEN 5 mg film-coated tablets. Pilocarpine hydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE USER SALAGEN 5 mg film-coated tablets Pilocarpine hydrochloride Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may
More informationPOLLENTYME S and Tabs Pharma Dynamics (Pty) Ltd Version: July 2017 (G1639) Word copy of G1639 PATIENT INFORMATION LEAFLET FOR POLLENTYME S AND TABS
PROPOSED FINAL PATIENT INFORMATION LEAFLET FOR POLLENTYME TABLETS & POLLENTYME S PATIENT INFORMATION LEAFLET SCHEDULING STATUS: S1 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: POLLENTYME TABLETS
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fluoride 5000 ppm Toothpaste 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g of toothpaste contains 5 mg fluoride (as sodium fluoride),
More informationThis leaflet answers some common questions about ATIVAN. It does not contain all of the available information.
Ativan Lorazepam Tablets Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about ATIVAN. It does not contain all of the available information. It does not
More informationStrength: 12.5mg/ 25mg/50mg. Pack Size: 100 Tablets per bottle Revision No.: 02
EMERGENCY OVERVIEW Each Promethazine Hydrochloride Tablet, USP intended for oral administration contains Promethazine Hydrochloride and excipients generally considered to be non- toxic and non-hazardous
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationThe prescribing newsletter for GPs, nurses and pharmacists NHS Northamptonshire Failure to respond to first choice antibiotics
Tablet Press EXTRA The prescribing newsletter for GPs, nurses and pharmacists NHS Northamptonshire Failure to respond to first choice antibiotics March 2017 Use of Buccolam (buccal midazolam) for breakthrough
More informationSAFETY DATA SHEET BWT-12 P
1. Product and Manufacturer Identification Product Name: Manufacturer: Apollo Technologies, Inc. 31441 Santa Margarita Parkway, Suite A-219 Rancho Santa Margarita, Ca. 92688 For more information call:
More informationPackage leaflet: Information for the patient. ROBAXIN mg Film-coated tablets for oral use Methocarbamol. 100 Tablets
Package leaflet: Information for the patient ROBAXIN - 750 750 mg Film-coated tablets for oral use Methocarbamol 100 Tablets Dosage: 2 tablets to be swallowed 4 times a day or as directed by your doctor.
More information